Literature DB >> 7535698

Antibodies that activate beta 2 integrins can generate different ligand binding states.

S Ortlepp1, P E Stephens, N Hogg, C G Figdor, M K Robinson.   

Abstract

A human erythroleukemic cell line (K562) that does not normally express beta 2 integrins has been transfected with the genes encoding these integrins. The resulting cell lines show minimal background adhesion but can be stimulated to bind to appropriate substrates when activated with either of two different antibodies to CD18. The two antibodies appear to generate different ligand binding states in LFA-1 such that different members of the ICAM family are recognized. Antibody-activated complement receptor type 3 and p150,95-transfected cells bind protein-coated surfaces, although they require slightly different activation conditions for optimal binding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535698     DOI: 10.1002/eji.1830250302

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

Review 1.  Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules.

Authors:  G E Davis; K J Bayless; M J Davis; G A Meininger
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Effects of I domain deletion on the function of the beta2 integrin lymphocyte function-associated antigen-1.

Authors:  B Leitinger; N Hogg
Journal:  Mol Biol Cell       Date:  2000-02       Impact factor: 4.138

3.  Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.

Authors:  V Vetvicka; B P Thornton; G D Ross
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

4.  An atomic resolution view of ICAM recognition in a complex between the binding domains of ICAM-3 and integrin alphaLbeta2.

Authors:  Gang Song; Yuting Yang; Jin-Huan Liu; Jose M Casasnovas; Motomu Shimaoka; Timothy A Springer; Jia-Huai Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

5.  A simple, no-wash cell adhesion-based high-throughput assay for the discovery of small-molecule regulators of the integrin CD11b/CD18.

Authors:  Jun Y Park; M Amin Arnaout; Vineet Gupta
Journal:  J Biomol Screen       Date:  2007-04

6.  CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus.

Authors:  Mohd Hafeez Faridi; Samia Q Khan; Wenpu Zhao; Ha Won Lee; Mehmet M Altintas; Kun Zhang; Vinay Kumar; Andrew R Armstrong; Carmelo Carmona-Rivera; Jessica M Dorschner; Abigail M Schnaith; Xiaobo Li; Yogita Ghodke-Puranik; Erica Moore; Monica Purmalek; Jorge Irizarry-Caro; Tingting Zhang; Rachael Day; Darren Stoub; Victoria Hoffmann; Shehryar Jehangir Khaliqdina; Prachal Bhargava; Ana M Santander; Marta Torroella-Kouri; Biju Issac; David J Cimbaluk; Andrew Zloza; Rajeev Prabhakar; Shashank Deep; Meenakshi Jolly; Kwi Hye Koh; Jonathan S Reichner; Elizabeth M Bradshaw; JianFeng Chen; Luis F Moita; Peter S Yuen; Wanxia Li Tsai; Bhupinder Singh; Jochen Reiser; Swapan K Nath; Timothy B Niewold; Roberto I Vazquez-Padron; Mariana J Kaplan; Vineet Gupta
Journal:  J Clin Invest       Date:  2017-03-06       Impact factor: 14.808

7.  The beta-tail domain (betaTD) regulates physiologic ligand binding to integrin CD11b/CD18.

Authors:  Vineet Gupta; Annette Gylling; José Luis Alonso; Takashi Sugimori; Petre Ianakiev; Jiang-Ping Xiong; M Amin Arnaout
Journal:  Blood       Date:  2006-12-14       Impact factor: 22.113

Review 8.  Aggregatibacter actinomycetemcomitans leukotoxin: From mechanism to targeted anti-toxin therapeutics.

Authors:  Eric Krueger; Angela C Brown
Journal:  Mol Oral Microbiol       Date:  2020-03-10       Impact factor: 3.563

9.  Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury.

Authors:  Mohd Hafeez Faridi; Mehmet M Altintas; Camilo Gomez; Juan Camilo Duque; Roberto I Vazquez-Padron; Vineet Gupta
Journal:  Biochim Biophys Acta       Date:  2013-02-26

10.  A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1.

Authors:  N Hogg; M P Stewart; S L Scarth; R Newton; J M Shaw; S K Law; N Klein
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.